Market Overview

UPDATE: Ascendiant Capital Markets Initiates POZEN at Buy; Future Royalties Attractive

Related POZN
Mid-Morning Market Update: Markets Open Lower; Goldman Sachs Q4 Profit Drops
POZEN And Tribute Announce Plan To Proceed With Merger To Form Aralez Pharmaceuticals, $350 Million Capital Commitment from Deerfield-Led Syndicate

Ascendiant Capital Markets initiated coverage on POZEN (NASDAQ: POZN) with a Buy rating and a $8.25 price target.

Ascendiant Capital Markets noted, "Pozen has a small number of employees (32), choosing instead to outsource much of its product development with strategic partners. The Company's strategy is to also out-license the manufacturing and sale of its products, for which it receives an upfront payment and a royalty percentage of total sales, avoiding the cost of maintaining a sales and marketing infrastructure. Hence, we believe that a growing stream of royalties could be highly leveraging to future net income and EPS."

POZEN closed at $6.43 on Monday.

Latest Ratings for POZN

Feb 2015Chardan CapitalInitiates Coverage onBuy
Aug 2014Ascendiant CapitalUpgradesHoldBuy
Apr 2013JefferiesTerminatesHold

View More Analyst Ratings for POZN
View the Latest Analyst Ratings

Posted-In: Ascendiant Capital MarketsAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (POZN)

View Comments and Join the Discussion!

Partner Center